Fosfomycin suppresses chemokine induction in airway epithelial cells infected with respiratory syncytial virus.
Respiratory syncytial virus (RSV) infects airway epithelial cells, causing bronchiolitis and pneumonia. Inflammation is mediated by various cytokines secreted from RSV-infected airway epithelial cells, and it promotes the pathogenesis of RSV-related diseases. Fosfomycin (FOF) is approved as a treatment for various bacterial infectious diseases, including respiratory infectious diseases, in Japan. FOF is suggested to exhibit immunomodulatory effects on lipopolysaccharide-stimulated monocytes and T lymphocytes, in addition to its antimicrobial activity. We investigated the effect of FOF on the cytokine production of an airway epithelial cell line, A549, infected with RSV. RSV-induced cytokines, such as regulated on activation, normal T-cell expressed and secreted (RANTES), interleukin-8 (IL-8), and IL-6, in infected A549 cells. We found that FOF decreased the levels of RSV-induced RANTES and IL-8 but not the level of RSV-induced IL-6. The RANTES promoter was activated by RSV infection. Site-directed mutagenesis analysis of the RANTES promoter showed that NF-kappaB-binding motifs had a critical role in RSV-induced RANTES promoter activity. A luciferase reporter gene assay and a DNA-binding assay indicated that FOF suppressed the NF-kappaB activity induced by RSV infection. These results demonstrate that FOF treatment suppresses the RSV-induced transcription of the chemokines RANTES and IL-8 in airway epithelial cells.
Okabayashi
Tamaki
T
Department of Microbiology, Sapporo Medical University School of Medicine, S1-W17, Chuou-ku, Sapporo, Hokkaido 060-8556, Japan.
Yokota
Shin-ichi
S
Yoto
Yuko
Y
Tsutsumi
Hiroyuki
H
Fujii
Nobuhiro
N
D002460:Cell Line; D018925:Chemokines / Q000096:biosynthesis*; D004847:Epithelial Cells / Q000187:drug effects / Q000276:immunology* / Q000821:virology*; D005578:Fosfomycin / Q000494:pharmacology*; D020869:Gene Expression Profiling; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology*; D016328:NF-kappa B / Q000037:antagonists & inhibitors; D012136:Respiratory Syncytial Viruses / Q000276:immunology*
D018925:Chemokines; D007155:Immunologic Factors; D016328:NF-kappa B; D005578:Fosfomycin